Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
Go back to Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 56.04 +0.51 (0.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.53 | 52 Week High | $77.12 | |||
| Open | $56.00 | 52 Week Low | $49.03 | |||
| Day High | $56.05 | P/E | 36.39 | |||
| Day Low | $56.00 | EPS | $1.54 | |||
| Volume | 150,436 | |||||
